Your browser is no longer supported. Please, upgrade your browser.
Settings
KIN Kindred Biosciences, Inc. daily Stock Chart
KIN [NASD]
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own5.40% Shs Outstand38.15M Perf Week3.26%
Market Cap326.18M Forward P/E- EPS next Y-1.17 Insider Trans51.67% Shs Float36.73M Perf Month0.59%
Income-55.80M PEG- EPS next Q-0.38 Inst Own65.70% Short Float2.34% Perf Quarter-1.27%
Sales2.50M P/S130.47 EPS this Y-30.20% Inst Trans15.37% Short Ratio4.89 Perf Half Y-19.11%
Book/sh3.18 P/B2.69 EPS next Y16.40% ROA-47.00% Target Price15.96 Perf Year-22.27%
Cash/sh2.52 P/C3.40 EPS next 5Y40.00% ROE-51.70% 52W Range7.56 - 15.75 Perf YTD-21.92%
Dividend- P/FCF- EPS past 5Y-7.30% ROI-56.20% 52W High-45.71% Beta0.43
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin83.20% 52W Low13.10% ATR0.37
Employees151 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)55.37 Volatility4.34% 4.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.30% Profit Margin- Rel Volume0.92 Prev Close8.10
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume176.03K Price8.55
Recom1.70 SMA206.24% SMA500.12% SMA200-20.66% Volume162,810 Change5.56%
Jun-11-19Initiated Barclays Overweight $13
May-23-19Initiated Stifel Buy
May-23-19Initiated Guggenheim Buy $11
Mar-07-19Reiterated Lake Street Buy $30 → $12
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
Jun-21-19 09:47AM  A Handful of Small Biotechs That Make for Merger Chatter TheStreet.com
May-13-19 08:31AM  Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational PR Newswire
May-10-19 01:24PM  Kindred Biosciences (KIN) Q1 2019 Earnings Call Transcript Motley Fool
01:50AM  Edited Transcript of KIN earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 06:15PM  Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:07PM  Kindred Bio: 1Q Earnings Snapshot Associated Press
04:01PM  Kindred Biosciences Announces First Quarter 2019 Financial Results PR Newswire
May-07-19 11:54AM  Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares? Simply Wall St.
Apr-25-19 08:01AM  Kindred Biosciences to Announce First Quarter 2019 Financial Results PR Newswire +5.90%
Mar-13-19 02:03AM  Edited Transcript of KIN earnings conference call or presentation 6-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-19 01:19PM  Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals Simply Wall St. -10.88%
Mar-06-19 09:21PM  Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Feb-19-19 08:31AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results PR Newswire
Feb-13-19 08:31AM  Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference PR Newswire
02:03AM  Kindred Group plc - Year end report January - December 2018 (Unaudited) PR Newswire
Jan-25-19 02:02PM  Bringing world class medication to animals Yahoo Finance Video
Jan-23-19 04:10PM  Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jan-22-19 08:31AM  Kindred Biosciences Named Best Company in North America by Leading Industry Publication PR Newswire
Jan-18-19 09:31AM  Kindred Biosciences Announces Pricing of Public Offering PR Newswire -8.03%
Jan-17-19 04:01PM  Kindred Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
Jan-14-19 07:01AM  Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital PR Newswire
Nov-16-18 08:35AM  Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-14-18 01:36AM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 04:01PM  Kindred Biosciences Announces Third Quarter 2018 Financial Results PR Newswire
Oct-30-18 04:01PM  Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent PR Newswire
Oct-24-18 08:31AM  Kindred Biosciences to Announce Third Quarter 2018 Financial Results PR Newswire -6.24%
Oct-23-18 07:31AM  Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President PR Newswire
Sep-17-18 08:31AM  Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Aug-30-18 08:31AM  Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit PR Newswire
Aug-26-18 11:55PM  Edited Transcript of KIN earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-21-18 08:31AM  Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference PR Newswire
Aug-09-18 04:01PM  Kindred Biosciences Announces Second Quarter 2018 Financial Results PR Newswire
Jul-16-18 08:31AM  Kindred Biosciences to Announce Second Quarter 2018 Financial Results PR Newswire
Jul-09-18 08:31AM  Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States PR Newswire
Jun-26-18 05:55PM  [$$] Kindred Biosciences' Top Holder Buys $8M More in Stock Barrons.com
Jun-25-18 09:01AM  Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock PR Newswire
Jun-20-18 04:01PM  Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program PR Newswire
09:10AM  Kindred Biosciences Announces Pricing of Public Offering PR Newswire
Jun-19-18 04:01PM  Kindred Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 06:46AM  Who Owns Most Of Prima Park SA. (WSE:KIN)? Simply Wall St.
May-30-18 07:02AM  KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses PR Newswire
May-29-18 08:02AM  Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference PR Newswire
May-24-18 07:02AM  Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference PR Newswire
May-14-18 01:41AM  Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 09:10AM  Unlocking The Value In Animal Medicine Forbes
May-09-18 07:05AM  Blog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz ACCESSWIRE
May-08-18 04:01PM  Kindred Biosciences Announces First Quarter 2018 Financial Results PR Newswire
10:15AM  Is Prima Park SA. (WSE:KIN) A Financially Sound Company? Simply Wall St.
May-07-18 04:43PM  This Peninsula company's new drug is the cat's meow the FDA says so American City Business Journals
09:11AM  Weight Gain Season for Felines The Wall Street Journal
07:00AM  Kindred Biosciences Receives FDA Approval of Mirataz (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats PR Newswire
Apr-25-18 04:02PM  Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors PR Newswire
Apr-24-18 04:02PM  Kindred Biosciences Provides Updates on Pending Drug Approvals PR Newswire
Apr-18-18 04:01PM  Kindred Biosciences to Announce First Quarter 2018 Financial Results PR Newswire
Mar-08-18 04:01PM  Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference PR Newswire
Mar-02-18 02:16PM  Edited Transcript of KIN earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 04:01PM  Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:30PM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 08:30AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results PR Newswire
Feb-13-18 08:30AM  Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit PR Newswire
Dec-21-17 08:02AM  KindredBio Announces Submission of European Medicines Agency Filing for Mirataz PR Newswire
Dec-04-17 08:02AM  KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses PR Newswire
Nov-19-17 08:51PM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:27PM  Kindred Bio reports 3Q loss Associated Press
04:01PM  Kindred Biosciences Announces Third Quarter 2017 Financial Results PR Newswire
10:40AM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-11-17 09:01AM  Kindred Biosciences to Announce Third Quarter 2017 Financial Results PR Newswire
Oct-05-17 04:01PM  Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference PR Newswire
Sep-11-17 09:00AM  Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof PR Newswire
Aug-30-17 09:02AM  Kindred Biosciences to Present at Upcoming Investor Conferences PR Newswire
Aug-12-17 05:40AM  Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-17 11:58PM  Kindred Bio reports 2Q loss Associated Press
04:01PM  Kindred Biosciences Announces Second Quarter 2017 Financial Results PR Newswire
06:40AM  Investor Network: Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-04-17 09:02AM  Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting PR Newswire
Aug-01-17 08:34AM  Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7 GlobeNewswire
Jul-24-17 09:01AM  Kindred Biosciences to Announce Second Quarter 2017 Financial Results PR Newswire
Jul-20-17 09:30AM  Zacks.com featured highlights: Logitech International, Herman Miller, Diodes, Willdan Group and Kindred Biosciences Zacks
Jul-12-17 08:56AM  Kindred Biosciences' stock drops after public stock offering MarketWatch
08:40AM  KindredBio Announces Pricing of Public Offering PR Newswire
Jul-11-17 04:10PM  KindredBio Announces Proposed Public Offering of Common Stock PR Newswire -7.65%
Jun-30-17 06:14AM  Will Kindred Biosciences (KIN) Continue to Surge Higher? Zacks -7.03%
Jun-26-17 07:30AM  Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta PR Newswire
Jun-15-17 08:01AM  Kindred Biosciences Added to the Russell 2000 Index PR Newswire
May-30-17 09:01AM  Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference PR Newswire
May-24-17 09:01AM  Kindred Biosciences to Present at 7th Annual LD Micro Invitational PR Newswire
May-11-17 07:46AM  Edited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-03-17 05:09PM  Kindred Bio reports 1Q loss Associated Press
04:01PM  Kindred Biosciences Announces First Quarter 2017 Financial Results PR Newswire
08:15AM  Investor Network: Kindred Biosciences, Inc. to Host Earnings Call Accesswire
May-01-17 07:02AM  Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses PR Newswire
Apr-24-17 08:32AM  Kindred Biosciences to Announce First Quarter 2017 Financial Results PR Newswire
Mar-16-17 04:01PM  Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit PR Newswire
Mar-08-17 01:04PM  KINDRED BIOSCIENCES, INC. Financials
Mar-07-17 08:30AM  Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology PR Newswire
Mar-01-17 04:18PM  Kindred Bio reports 4Q loss Associated Press
04:08PM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:01PM  Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Kindred Biosciences Inc Earnings Release - After Market Close
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Park West Asset Management LLC10% OwnerJan 18Buy9.50741,8407,047,4806,743,893Jan 23 04:23 PM
Chin RichardChief Executive OfficerJan 02Sale10.5740,000422,7161,906,071Jan 04 08:41 PM
Chin RichardChief Executive OfficerDec 03Sale13.2840,000531,2001,946,071Dec 04 07:00 PM
Chin RichardCEONov 01Sale14.6840,000587,2001,986,071Nov 02 07:47 PM
MARIO ERNESTDirectorOct 29Option Exercise3.4144,833152,941169,000Oct 31 06:56 PM
Chin RichardPresident and CEOOct 01Sale13.2840,000531,2002,026,071Oct 03 05:15 PM
Townsend RaymondDirectorSep 26Sale13.302,88538,37124,928Sep 27 08:49 PM
Townsend RaymondDirectorSep 25Sale13.801151,58727,813Sep 27 08:49 PM
Chin RichardPRESIDENT AND CEOSep 05Sale14.697,600111,6442,066,071Sep 06 08:07 PM
Chin RichardPRESIDENT AND CEOSep 04Sale14.8132,400479,8442,073,671Sep 06 08:07 PM
Chin RichardPresident and CEOAug 01Sale13.5140,000540,4002,106,071Aug 03 09:06 PM
Chin RichardPresident and CEOJul 02Sale10.2840,000411,2002,146,071Jul 03 05:57 PM